X0306 4 2012-07-30 1 0000901219 HUMAN GENOME SCIENCES INC HGSI 0001241221 HA NGOC TUAN 14200 SHADY GROVE ROAD ROCKVILLE MD 20850 1 Common Stock 2012-07-30 4 D 0 4166.0000 14.2500 D 16807.0000 D Common Stock 2012-07-30 4 U 0 16807.0000 14.2500 D 0.0000 D Non-Employee Director Stock Option - Right to Buy 11.3300 2012-07-30 4 D 0 16000.0000 14.2500 D 2016-04-27 Common Stock 16000.0000 0.0000 D Non-Employee Director Stock Option - Right to Buy 10.7000 2012-07-30 4 D 0 16000.0000 14.2500 D 2017-05-03 Common Stock 16000.0000 0.0000 D Non-Employee Director Stock Option - Right to Buy 2.0900 2012-07-30 4 D 0 16000.0000 14.2500 D 2019-05-07 Common Stock 16000.0000 0.0000 D Non-Employee Director Stock Option - Right to Buy 5.9700 2012-07-30 4 D 0 16000.0000 14.2500 D 2018-05-08 Common Stock 16000.0000 0.0000 D Non-Employee Director Stock Option - Right to Buy 14.2300 2012-07-30 4 D 0 16000.0000 14.2500 D 2022-05-17 Common Stock 16000.0000 0.0000 D Non-Employee Director Stock Option - Right to Buy 9.3800 2012-07-30 4 D 0 25000.0000 14.2500 D 2015-12-01 Common Stock 25000.0000 0.0000 D Each restricted stock unit represents a contingent right to receive one (1) share of Human Genome Sciences, Inc. common stock. These restricted stock units were cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $59,365.50, ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc. These restricted stock units vested automatically upon consummation of the tender offer on July 30, 2012. This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $46,720.00, representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc. These options vested automatically upon consummation of the tender offer on July 30, 2012. This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $56,800.00, representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc. These options vested automatically upon consummation of the tender offer on July 30, 2012. This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $194,560.00, representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc. These options vested automatically upon consummation of the tender offer on July 30, 2012. This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $132,480.00, representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc. These options vested automatically upon consummation of the tender offer on July 30, 2012. This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $320.00, representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc. These options vested automatically upon consummation of the tender offer on July 30, 2012. This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $121,750.00, representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc. These options vested automatically upon consummation of the tender offer on July 30, 2012. /s/James H. Davis (Power of Attorney) on behalf of 2012-08-01